Drug Trial Radar · NCT06223048
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
Last checked: Nov 19, 2026Latest source record: Jul 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Dec 7, 2023
Primary completion
Nov 2024
Study completion Feb 2025
Sponsor
- Lead sponsor
- Amydis Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
Conditions
- Primary Open Angle Glaucoma
Interventions
AMDX-2011PDrug
AMDX-2011P single bolus injection intravenous for diagnostic review
Primary outcomes
What the sponsor says the trial is designed to measure.
- AMDX-2011P Adverse Events ProfileTime frame: 8 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Associated Retina Consultants
Phoenix, Arizona · Recruiting
Global Research Management
Glendale, California · Recruiting
Eye Research Foundation
Newport Beach, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.